Stock Events

Stock Events

Transgene. 

€0.78
18
+€0.01+1.69% Friday 15:29

Statistics

Day High
0.79
Day Low
0.77
52W High
1.5
52W Low
0.53
Volume
29,775
Avg. Volume
-
Mkt Cap
103.93M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Aug 14
€0
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

24MarExpected
Q2 2022
Q3 2022
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0.24
0.09
0.42
0.76
Expected EPS
N/A
Actual EPS
N/A

Financials

-558.64%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
12.16MRevenue
-67.94MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TNG.PA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap19.51B
Moderna is a leader in mRNA technology, competing in the development of vaccines and therapeutics, a space Transgene is also exploring with its viral vector-based immunotherapies.
BioNTech
BNTX
Mkt Cap22.92B
BioNTech competes directly with Transgene in the development of personalized cancer vaccines and other immunotherapies, leveraging mRNA technology.
Novavax
NVAX
Mkt Cap1.25B
Novavax is involved in the development of vaccines for infectious diseases, competing with Transgene's therapeutic vaccine development efforts.
Inovio Pharmaceuticals
INO
Mkt Cap78.07M
Inovio Pharmaceuticals is engaged in the development of DNA-based immunotherapies and vaccines, competing in the same space as Transgene's viral vector-based therapies.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, with its broad portfolio of antiviral drugs and cancer therapies, competes in the oncology and infectious disease sectors where Transgene is active.
AMGEN
AMGN
Mkt Cap187.56B
Amgen, with its focus on human therapeutics, including oncology and immunology, competes with Transgene in the development of treatments for cancer and infectious diseases.
Pfizer
PFE
Mkt Cap161.09B
Pfizer's extensive research in vaccines and cancer treatments makes it a competitor to Transgene, especially in the development of innovative immunotherapies.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the development of vaccines and immunotherapies, overlapping with Transgene's focus areas.
Merck
MRK
Mkt Cap298.84B
Merck is known for its strong pipeline in cancer immunotherapy and vaccines, directly competing with Transgene's efforts in developing similar therapeutic solutions.

About

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Show more...
CEO
Dr. Alessandro Riva M.D.
Employees
147
Country
France
ISIN
FR0005175080

Listings

STU
DE
TGNA.STU
MU
DE
TGNA.MU
F
DE
TGNA.F
OTC Link
US
TRGNF

0 Comments

Share your thoughts

FAQ

What is Transgene. stock price today?▼
The current price of TNG.PA is €0.78 EUR — it has increased by +1.69% in the past 24 hours. Watch Transgene. stock price performance more closely on the chart.
What is Transgene. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Transgene. stocks are traded under the ticker TNG.PA.
Is Transgene. stock price growing?▼
TNG.PA stock has risen by +5.81% compared to the previous week, the month change is a +0.38% rise, over the last year Transgene. has showed a +23.5% increase.
What is Transgene. market cap?▼
Today Transgene. has the market capitalization of 103.93M
When is the next Transgene. earnings date?▼
Transgene. is going to release the next earnings report on September 24, 2026.
What is Transgene. revenue for the last year?▼
Transgene. revenue for the last year amounts to 12.16M EUR.
What is Transgene. net income for the last year?▼
TNG.PA net income for the last year is -67.94M EUR.
Does Transgene. pay dividends?▼
Yes, TNG.PA dividends are paid en. The last dividend per share was 0 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Transgene. have?▼
As of April 12, 2026, the company has 147 employees.
In which sector is Transgene. located?▼
Transgene. operates in the Health & Wellness sector.
When did Transgene. complete a stock split?▼
Transgene. has not had any recent stock splits.
Where is Transgene. headquartered?▼
Transgene. is headquartered in Illkirch-Graffenstaden, France.